Announced Date: 2025-06-13 (June 13, 2025)
Licensor: CSPC (CSPC Pharmaceuticals Group Limited. , China)
Licensee: AstraZeneca（UK）
Collaboration Object: AI-enabled, advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.
.
Scope of Collaboration:
Discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases. The research will be carried out by CSPC, in Shijiazhuang City and will utilise their AI-driven, dual-engine efficient drug discovery platform.
AstraZeneca will have rights to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under this agreement.
.
Deal Detail:
Upfront payment and near term payment $110 million;
Development milestone payments up to $1.62 billion;
Sales milestone payments up to $3.6 billion;
Total up to $5.33 billion.
Additional potential single digit royalties based on annual net sales of the products.
.
Link:
AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
